AGIO Stock Cracks After Sickle-Cell Disease Drug Delivers Mixed Results In Late-Stage Trial
Synopsis
While Mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises (SCPCs) compared to placebo, this trend did not achieve statistical significance, Agios said.
Shares of Agios Pharmaceuticals, Inc. (AGIO) slumped 49% in the pre-market session on Wednesday after the company reported mixed results from its drug trial in sickle cell disease.
The company said that the late-stage study of Mitapivat in patients aged 16 years and older with sickle cell disease met the primary endpoint of hemoglobin response, with the drug demonstrating a statistically significant improvement compared to placebo.
Hemoglobin response is defined as an increase from baseline in average hemoglobin in a particular time frame.
While Mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises (SCPCs) compared to placebo, this trend did not achieve statistical significance, the company noted.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.